IN THE NEWS

« Previous Release | Next Release »

BOTHELL, Wash., -- Cardiac Science, a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, completed a three-year agreement for product design and engineering services from Colorado-based Syncroness, a leading design and engineering firm serving the medical devices industry.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)

"We expect considerable savings and speed-to-market improvements with Syncroness," said Bob Odell, vice president of engineering for Cardiac Science. The agreement increases Cardiac Science's engineering capacity to manage sustaining activities and new business opportunities. Odell adds, "This will allow seasoned Cardiac Science team members to focus on new customer solutions, revenue opportunities, and new advances in technology. As a result, we'll be even faster and more responsive to market needs."

"We've worked with Cardiac Science on a smaller scale and I can say they are a great partner," said chief marketing officer Jorg Lorscheider. "I'm confident we will reward Cardiac Science's trust with lowered costs, product development efficiencies, and an improved speed-to-market."

About Cardiac Science

Cardiac Science, a wholly owned subsidiary of Opto Circuits (India) Ltd., develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick^®, HeartCentrix^®, Powerheart^®, and Quinton^® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

Forward-Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's future AED sales in Japan, expected shipments of backordered products in the fourth quarter of 2010, and expectations regarding the closing of the transaction with Opto Circuits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

For updates and information on worldwide defibrillation and cardiac monitoring, find us on Facebook at http://facebook.com/cardiacscience, the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, and YouTube at http://budurl.com/CSonYT

For more information, contact (media) info@cardiacscience.com | (investors) ir@optoindia.com | +91.80.2852.8088